dentro de :
Neurometrix Inc(NASDAQ:NURO)
ventas ascendiendo y costos redcuciendose
The company saw a significant increase in the shipment of the SENSUS system for the quarter as well. It reported that it shipped 557 devices in Q3, up from 210 in Q2 2013, and 145 devices in Q1.
. The sales for the new system are increasing quarter over quarter, while the operating expenses are decreasing quarter over quarter. While the company is not profitable right now it looks like it is on the right track to change that in the near future. While I would say it is a good buy at this time there are some concerns. One is the fact that the company didn't have any real guidance during the CC or in its ER release. The other concern is the fact that there is no data right now on long-term patient retention. One last concern is the fact that another company could release a similar device in the near future. Taking the concerns into consideration I would still rate this company a good buy. The upside potential outweighs the downside risk by a good margin.
capitalizacion $ 7 millones, ventas totales de ultimos 4 trimestres 5.4 millones pero un aumento de envios del SENSUS system, respecto al trimestre anterior, para tratamiento de dolor en diabeticos de 210 a 557, o un aumento de 557/210 = 2.65 o ...... 165%
!!!!!!
Earnings per share, aunque fue perdida, de -0.92 a -0.26,---> -0.92/(-0.26) = 3.53, mejoria del 253% !!!!!
https://www.google.com/finance?q=NASDAQ%3ANURO&fstype=ii&ei=gVGZUtiDEa23iAK1jwE
sigo dentro de IPCI, CTSO, VTUS, SNGX ....
